

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO FORM 1449**

Atty. Docket No.  
1662/60903

Serial No.  
10/649,399

Applicant(s)  
Dolitzky et al.

Filing Date  
August 26, 2003

Group  
1624



**U. S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

\* - If pertinent

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
<i>[Signature]</i>	0 885 223 B1	Dec. 23, 1998	Europe				
<i>[Signature]</i>	WO 97/29108	Aug. 14, 1997	PCT				

\* Copy of reference is not enclosed because reference is cited in Search Report (copy of reference provided by International Searching Authority).

**OTHER DOCUMENTS**

EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
<i>[Signature]</i>	M. R. Hamden et al., Nucleosides & Nucleotides 9(4):499-513 (1990)
<i>[Signature]</i>	John Haleblan et al "Pharmaceutical Applications of Polymorphism"; Journal of Pharmaceutical Sciences, Vol. 58, No. 8, August 1969 - PP.911 - 929.
<i>[Signature]</i>	John K. Haleblan "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications"; Journal of Pharmaceutical Sciences, Vol. 64, No. 8, August 1975 - PP1269 - 1288.
<i>[Signature]</i>	G. Michael Wall "Pharmaceutical Applications of Drug Crystal Studies", Pharmaceutical Manufacturing, Vol. 3, No.2, February 1986; PP 33-42.

EXAMINER

*[Signature: Man Boud]*

DATE CONSIDERED

*[Signature: 8/24/03]*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.